EuroBiotech: More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> DBV Technologies priced a $150 million (€121 million) stock offering. The round precedes a planned submission for approval of a peanut allergy therapy in the U.S. Statement

> Motif Bio delayed a filing for approval of its antibiotic, iclaprim. The biotech now plans to submit an application to the FDA in the second quarter. Release

>  Bavarian Nordic entered into a collaboration with the U.S. Department of Defense to develop a vaccine against the equine encephalitis virus. The deal is worth up to $36 million (€29 million). Statement

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Shield Therapeutics outlined the analyses it presented to the FDA at a pre-NDA meeting. The pivotal trial missed its hematology-focused primary endpoint, but Shield thinks the result was affected by confounding data. Shield is now waiting to learn the FDA’s take. Release

> Arix Bioscience raised £87 million ($123 million) from new and existing investors. The financing will enable Arix to add to the 13 investments it has made so far. Statement

> Deinove secured an option on Redx Pharma’s bacterial topoisomerase inhibitor program. The deal gives Deinove nine months to evaluate the program before deciding whether to pay a fee to exercise its option. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.